









Markets
/
Stocks
/
nasdaq-cycn
/

Cyclerion Therapeutics Inc

CYCN



View Detailed Chart

1.380USD

-0.050-3.50%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

5.10MMarket Cap

LossP/E TTM



Cyclerion Therapeutics Inc

1.380

-0.050-3.50%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-3.50%

5 Days

-9.21%

1 Month

-7.38%

6 Months

-53.94%

Year to Date

-57.14%

1 Year

-58.05%

View Detailed Chart

TradingKey Stock Score of Cyclerion Therapeutics Inc

Currency: USD Updated: 2025-12-24

Key Insights

Cyclerion Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 214/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cyclerion Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

214 / 404

Overall Ranking

394 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cyclerion Therapeutics Inc Highlights

StrengthsRisks

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 573.40% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.00M.

Fairly Valued

The company’s latest PE is -1.96, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 23.49K shares of this stock.